EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis

Krzysztof Michalak iD, Gabriela Chlebowska iD, Oliwia Sędziak iD, Dariusz Woszczyk iD

Rheumatology · 10.07.2026 · 64 (4) · 322-331

DOI: 10.5114/reum/224664 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Rheumatology, online erschienen am 10.07.2026. Verfasst von Krzysztof Michalak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Medical Sciences, University of Opole, Poland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Systemic sclerosis (SSc) remains a challenge due to high mortality and resistance to treatment. Chimeric antigen receptor T-cell (CAR-T) technology (anti-CD19) may offer an opportunity for an immune system reset and long-term disease remission, eliminating the need for lifelong medication. Material and Methods This narrative review is based on a literature search in the PubMed and Scopus databases from 2023 to 2026. The main search phrases were: “CAR-T in systemic sclerosis”, “CAR-T scleroderma”, and “CAR-T SSc.” Results CD19-targeted CAR-T therapy led to significant clinical improvement across analyzed cases. The median modified Rodnan skin score decreased by 8–13 points within 3–6 months. Disease activity, measured by the European Scleroderma Trials and Research Group Activity Index (EUSTAR-AI), showed a mean improvement ranging from 2.1 to 4.2 points. Pulmonary function remained stable or improved, with forced vital capacity increasing by up to 7% in responders. The safety profile was manageable, primarily consisting of grade 1 cytokine release syndrome in approximately 75–80% of patients.

Conclusions

CD19-targeted CAR-T therapy is a promising investigational option for patients with refractory SSc. Limitations include small study groups and a lack of randomized controlled trials, warranting further validation in ongoing clinical studies.

Schlagwörter

Stichwörter der Autor:innen

immunotherapysclerodermasystemic sclerosis

Autor:innen und Institutionen

  • Department of Hematology, Institute of Medical Sciences, University of Opole, Poland.

ORCID-Profile: Krzysztof Michalak, Gabriela Chlebowska, Oliwia Sędziak, Dariusz Woszczyk

Zitieren

APA

Michalak, K., Chlebowska, G., Sędziak, O., & Woszczyk, D. (2026). The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis. Rheumatology, 64(4), 322-331. https://doi.org/10.5114/reum/224664

Vancouver

Michalak K, Chlebowska G, Sędziak O, Woszczyk D. The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis. Rheumatology. 2026;64(4):322-331. doi:10.5114/reum/224664

BibTeX
@article{Michalak2026,
  author = {Michalak, Krzysztof and Chlebowska, Gabriela and Sędziak, Oliwia and Woszczyk, Dariusz},
  title = {The role and potential of CD19-targeted chimeric antigen receptor T-cell therapy in systemic sclerosis},
  journal = {Rheumatology},
  year = {2026},
  volume = {64},
  number = {4},
  pages = {322--331},
  doi = {10.5114/reum/224664}
}
Kostenlos starten →